GSK expected to follow AstraZeneca in cost-cutting agenda
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is expected to reveal more than 3,000 job cuts as part of a restructuring to be announced in its annual results later this week. The company will reduce investment in some disease areas and develop its non-core pharmaceutical business, according to UK press reports.